Sweet syndrome after <scp>Oxford‐AstraZeneca COVID</scp>‐19 vaccine (<scp>AZD1222</scp>) in an elderly female
Imran Majid, Samia Mearaj
Abstract
Vaccination for COVID19 infection is in full swing all around the world and while the vaccines are considered overall safe, many cutaneous and extracutaneous adverse effects have been reported after their use. Local injection-site reactions are the commonest adverse effect described with the use of these vaccines. We describe a case of Sweet syndrome in an elderly female after the first dose of Oxford-AstraZeneca COVID-19 vaccine (AZD1222).
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Adverse effectVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyImmunologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)Autoimmune and Inflammatory DisordersAutoimmune Bullous Skin DiseasesTumors and Oncological Cases